

**Methodological note on the publication of resulting benefits
from the cooperation of Boehringer Ingelheim Sp. z o.o. with Patient Organizations.**

The rules for publishing information on services provided to Patient Organizations by innovative pharmaceutical companies result from the **INFARMA Code of Good Practice**. Each Signatory of the Code is obliged to develop its own methodological note and publish it together with reports on the benefits provided.

Introduction

As a Signatory of the INFARMA Code of Good Practice, we are obliged to provide the public with information about the scope of our cooperation with Patient Organizations in an understandable and transparent manner.

Boehringer Ingelheim supports organizations that work for patients and their family caregivers. At the same time, we apply the highest and objective standards of cooperation, taking into account the absence of any conflict of interest. Sharing information about support and agreements with Patient Organizations is intended to help ensure fair and substantive cooperation in the interests of patients and contribute to a better understanding by the public of the high value of this cooperation.

By Patient Organization we mean a non-for-profit entity of patients or their caregivers that represents or supports patients of their caregivers as well as an organization of such entities, with its registered office or main place of business in Europe.

Method of determining the value of the benefit

The benefits were indicated in the amount in which they constitutes the cost for the Company. The value of benefits is disclosed in Polish Zlotys and in case of support from abroad in euros.

How information is published

Data of financial and material benefits are published annually. The reporting period covers a full calendar year from 01/01/2023 to 31/12/2023, with the report being published no later than 30 June of the following year. Information on benefits for Patient Organizations presents the amounts of benefits provided in a given reporting period.

Information will be disclosed on the Boehringer Ingelheim website in Polish at www.boehringer-ingelheim.pl and in English at www.boehringer-ingelheim.at .

Boehringer Ingelheim will publish information for 3 years from the date of the first disclosure.